1 |
STUDIES OF GENERAL CLINICAL AND CHEMICAL-MICROSCOPIC PARAMETERS (blood, urine, stay, high humidity) |
|
2 |
General blood analysis (OAK) |
450 |
3 |
clotting time |
150 |
4 |
Bleeding duration |
150 |
5 |
Study of the level of reticulocytes in the blood |
250 |
6 |
The study of the level of platelets in the blood |
250 |
7 |
General urine analysis (OAM) |
240 |
8 |
Microscopic examination of urine sediment |
240 |
9 |
Urinalysis using the Nechiporenko method |
240 |
10 |
Urinalysis using the Zimnitsky method |
350 |
11 |
Three glass urine sample |
500 |
12 |
Feces for occult blood (qualitative) |
250 |
13 |
Coprogram |
350 |
14 |
Examination of feces for helminth eggs and protozoa |
300 |
15 |
Examination of feces for helminth eggs and protozoa by enrichment |
650 |
16 |
Calprotectin, (stay) |
2 |
17 |
Pancreatic elastase 1, (stay) |
2 |
18 |
Carbohydrates in feces (Benedict's trial) |
500 |
19 |
Scrape for enterobiosis |
300 |
20 |
General sputum analysis |
450 |
21 |
STUDY OF BIOCHEMICAL PARAMETERS |
|
22 |
total protein, (blood) |
175 |
23 |
Protein fractions (blood) |
350 |
24 |
Albumin, (blood) |
210 |
25 |
C-reactive protein (SRB), (blood) |
300 |
26 |
Urea, (blood) |
175 |
27 |
Creatinine, (blood) |
175 |
28 |
Reberga sample (blood and urine) |
200 |
29 |
Glomerular filtration rate (SKF) per creatinine |
250 |
30 |
Uric acid, (blood) |
175 |
31 |
Lipid spectrum (blood: TG, total cholesterol , HDL cholesterol, LDL cholesterol, VLDL cholesterol, atherogenic coefficient) |
750 |
32 |
total cholesterol, (blood) |
200 |
33 |
Triglycerides, (blood) |
200 |
34 |
low density lipoprotein cholesterol (LDL), (blood) |
240 |
35 |
high density lipoprotein cholesterol (HDL), (blood) |
210 |
36 |
Apoprotein A1, (blood) |
470 |
37 |
Apoliprotein B, (blood) |
350 |
38 |
Aspartate aminotransferase (IS), (blood) |
175 |
39 |
Alanine aminotransferase (GOLD), (blood) |
175 |
40 |
Bilirubin total, (blood) |
175 |
41 |
Bilirubin direct, (blood) |
175 |
42 |
Gamma-glutamyl transpeptidase (GGTP), (blood) |
175 |
43 |
Lactate dehydrogenase (LDH), (blood) |
175 |
44 |
Alkaline phosphatase (Shtf), (blood) |
175 |
45 |
Alpha amylase, (blood) |
175 |
46 |
Alpha-amylase pancreatic, (blood) |
275 |
47 |
Lipase, (blood) |
320 |
48 |
Creatine phosphokinase (KFC), (blood) |
240 |
49 |
Creatine phosphokinase MV-fraction (blood; KFC-MV) |
270 |
50 |
angiotensin converting enzyme (blood; APF) |
2 |
51 |
Glucose, (blood) |
175 |
52 |
Glucose tolerance test (blood; GTT) |
600 |
53 |
Glucose (capillary blood) |
150 |
54 |
Glycemic profile (blood; 2 points) |
300 |
55 |
Glycemic profile (blood; 3 points) |
450 |
56 |
Glycemic profile (blood; 6 points) |
800 |
57 |
The study of blood glucose levels by continuous monitoring |
6 |
58 |
Lactate (blood) |
500 |
59 |
Fructosamine (blood) |
850 |
60 |
Glycosylated hemoglobin (blood; HbA1C) |
385 |
61 |
Homocysteine |
1 |
62 |
Albumin (urine) |
320 |
63 |
Glucose (urine) |
175 |
64 |
Alpha amylase (urine) |
175 |
65 |
Albumin to creatinine ratio (urine) |
450 |
66 |
Creatinine (urine) |
175 |
67 |
Determination of the amount of protein in daily urine (daily urine) |
175 |
68 |
Detection of ketone bodies in urine by express method (urine) |
120 |
69 |
STUDY OF PARAMETERS OF THE HEMOSTASIS SYSTEM (blood) |
|
70 |
prothrombin index (PTI) |
175 |
71 |
Prothrombin, MANY (prothrombin time) |
250 |
72 |
Activated partial thromboplastin time (АХТВ) |
200 |
73 |
thrombin time (TV) |
230 |
74 |
D-dimer (quantitatively) |
1 |
75 |
Plasminogen |
425 |
76 |
Protein C |
1 |
77 |
Fibrinogen |
240 |
78 |
Antithrombin III |
390 |
79 |
RFMK (soluble fibrin monomer complex) |
200 |
80 |
Screening study of the hemostasis system (TV, APTV, MANY, fibrinogen, D-dimer) |
1 |
81 |
Detailed study of the hemostasis system (TV, APTV, MANY, fibrinogen,D-dimer,antithrombin III, plasminogen, protein C, lupus anticoagulant) |
3 |
82 |
STUDY OF INORGANIC SUBSTANCES, ELECTROLYTES, VITAMINS |
|
83 |
Potassium (blood) |
120 |
84 |
Sodium (blood) |
120 |
85 |
chlorides (blood) |
120 |
86 |
Phosphorus (blood) |
175 |
87 |
Magnesium (blood) |
175 |
88 |
Calcium total (roof) |
175 |
89 |
Calcium ionized (blood) |
350 |
90 |
Copper (blood) |
1 |
91 |
25-OH vitamin D |
1 |
92 |
Oxalates (daily urine) |
1 |
93 |
Potassium (urine) |
135 |
94 |
Sodium (urine) |
135 |
95 |
chlorides (urine) |
135 |
96 |
Comprehensive study of iron metabolism (blood; Fe, OHSS, LWSS, saturation factor) |
450 |
97 |
Iron (blood) |
175 |
98 |
Vitamin B12 (blood) |
590 |
99 |
Folic acid (blood) |
540 |
100 |
RESEARCH OF HORMONES |
|
101 |
Thyroid hormone (The CIA) |
300 |
102 |
Triiodothyronine total (T3) |
320 |
103 |
Triiodothyronine free (T3st) |
320 |
104 |
Thyroxine general (T4) |
320 |
105 |
thyroxine free (T4 St) |
320 |
106 |
Prolactin |
380 |
107 |
C-peptide (blood) |
440 |
108 |
Insulin (blood) |
530 |
109 |
Proinsulin (blood) |
690 |
110 |
Erythropoietin |
860 |
111 |
luteinizing hormone (LG) |
380 |
112 |
Follicle stimulating hormone (FSH) |
380 |
113 |
Estradiol |
380 |
114 |
Estradiol free |
495 |
115 |
Progesterone |
380 |
116 |
Testosterone total |
380 |
117 |
testosterone free |
800 |
118 |
Dihydrotestosterone (DHT) |
990 |
119 |
Dehydroepiandrosterone sulfate (DGEA) |
380 |
120 |
17-hydroxyprogesterone (blood; 17-OKS) |
500 |
121 |
Cortisol (urine) |
620 |
122 |
Cortisol (blood) |
420 |
123 |
growth hormone (STG) |
480 |
124 |
Insulin-like growth factor I (IFR) |
940 |
125 |
Anti-Müllerian hormone (AMG) |
1 |
126 |
Parathyroid hormone |
600 |
127 |
Adrenocorticotropic hormone (ACTH) |
680 |
128 |
Nephrines: methenephrine, normetanephrine, (blood) |
1 |
129 |
Catecholamine (adrenaline, norepinephrine, dopamine) |
1 |
130 |
Aldosterone |
460 |
131 |
Androstenedione |
900 |
132 |
Renin |
690 |
133 |
Aldosterone-renin ratio (Aldosterone-Renin Ratio, ARR) |
1 |
134 |
Pepsinogen I |
460 |
135 |
Pepsinogen II |
460 |
136 |
Gastrin |
570 |
137 |
Catecholamine (adrenaline, norepinephrine, dopamine; urine) |
2 |
138 |
17-hydrocorticosteroid, (17-OKS; urine) |
1 |
139 |
free cortisol (daily urine) |
620 |
140 |
Nephrines: methenephrine, normetanephrine (daily urine) |
1 |
141 |
Beta chorionic gonadotropin (hCG) |
380 |
142 |
STUDYING MARKERS OF ANEMIA |
|
143 |
Iron (blood) |
175 |
144 |
Total iron-binding capacity of serum (OHSS) |
175 |
145 |
Serum latent iron-binding capacity (LWSS) |
215 |
146 |
Comprehensive study of iron metabolism (blood; Fe, OHSS, LWSS, saturation factor) |
450 |
147 |
Vitamin B12 (blood) |
590 |
148 |
Folic acid (blood) |
540 |
149 |
Erythropoietin |
860 |
150 |
STUDIES OF ONCOMARKERS AND SPECIFIC PROTEINS |
|
151 |
Cancer embryonic antigen (REA) |
550 |
152 |
Alpha fetoprotein |
385 |
153 |
prostate-specific antigen common (PSA) |
450 |
154 |
free prostate-specific antigen (PSA free) |
450 |
155 |
PHI index (PSA total, PSA free, for PSA-2) |
2 |
156 |
CA 19-9 (Carbohydrate antigen CA 19-9) |
620 |
157 |
CA-125 (Cancer antigen 125) |
550 |
158 |
THAT 15.3 (Cancer antigen 15-3) |
600 |
159 |
CA-242 (Carbohydrate antigen CA-242) |
710 |
160 |
Comprehensive examination of ovarian cancer (NO4, SA125, index ROMA1; ROMA2 index) |
1 |
161 |
WITH 72-4 (Carbohydrate antigen 72-4) |
750 |
162 |
Soluble fragment of cytokeratin 19 (DIGIT 21.1) |
770 |
163 |
Neuron-specific enolase. (NSE) |
1 |
164 |
Protein S-100 |
1 |
165 |
Squamous cell carcinoma antigen (SCC) |
1 |
166 |
UBS (bladder cancer marker) (urine) |
1 |
167 |
Trophoblast glycoprotein (TBG) |
350 |
168 |
Beta chorionic gonadotropin (hCG) |
380 |
169 |
Prenatal screening 2 trimester: AFP, hCG, NE (PRISCUS II) |
1 |
170 |
HE4 (Protein 4 human epididymis) |
940 |
171 |
Troponin T quality, (blood) |
550 |
172 |
Antistreptolysin-O (ABSOLUTELY), (blood) |
350 |
173 |
Cerulloplasmin, (blood) |
550 |
174 |
Beta-2 microglobulin, (blood) |
720 |
175 |
Bence Jones protein (urine) |
1 |
176 |
myoglobin, (blood) |
600 |
177 |
N-terminal fragment of the natriuretic propeptide of the brain (NT-proBNP), (blood) |
2 |
178 |
Osteocalcin |
590 |
179 |
Procalcitonin |
1 |
180 |
Calcitonin |
750 |
181 |
Transferrin (blood) |
400 |
182 |
Ferritin (blood) |
510 |
183 |
Neopterin |
1 |
184 |
MICROSCOPIC AND CYTOLOGICAL STUDIES |
|
185 |
Blood microscopy for detection of LE cells |
1 |
186 |
Microscopic examination of a thin blood smear for malarial plasmodia (Plasmodium) |
500 |
187 |
Microscopic examination of urine for Mycobacterium tuberculosis (Mycobacterium tuberculosis) |
450 |
188 |
Microscopic examination of native and stained sputum preparation |
450 |
189 |
Cytological examination of sputum |
650 |
190 |
Cytological examination of urine for atypical cells |
550 |
191 |
Cytological examination of micropuncture of the thyroid gland |
500 |
192 |
Cytological examination of scrapings from the cervix and cervical canal |
480 |
193 |
Microscopic study of duodenal contents |
1 |
194 |
Minute study of duodenal contents with a conclusion |
1 |
195 |
duodenal sounding (with flushing) |
2 |
196 |
Cytological examination of punctates, scrapings |
550 |
197 |
Microscopic examination of the prostate secretion sediment |
550 |
198 |
Microscopy of skin scrapings |
550 |
199 |
Microscopic examination of lavage fluid for atypical cells |
550 |
200 |
Microscopic examination of the lavage fluid on the VC |
550 |
201 |
Rhinocytogram |
450 |
202 |
CLINICAL AND MICROBIOLOGICAL STUDIES, CULTURAL (bacterial crops) |
|
203 |
Bacteriological examination of mucus from the tonsils and posterior pharyngeal wall for aerobic and facultative anaerobic microorganisms |
550 |
204 |
Bacteriological study of swabs from the paranasal cavities for aerobic and facultative anaerobic microorganisms |
550 |
205 |
Bacteriological examination of swabs from the paranasal cavities for Staphylococcus aureus (Staphylococcus aureus) |
300 |
206 |
Bacteriological examination of mucus from the tonsils and posterior pharyngeal wall for Staphylococcus aureus (Staphylococcus aureus) |
300 |
207 |
Mycological examination of nasopharyngeal swabs for fungi of the genus Candida (Candida spp.) |
250 |
208 |
Mycological examination of oral scrapings for fungi of the genus Candida (Candida spp.) |
250 |
209 |
Bacteriological examination of discharge from the ears for aerobic and facultative anaerobic microorganisms |
550 |
210 |
Mycological examination of discharge from the ears for fungi of the genus Candida (Candidа spp.) |
250 |
211 |
Bacteriological examination of sputum for aerobic and facultative anaerobic microorganisms |
700 |
212 |
Bacteriological study of lavage fluid for aerobic and facultative anaerobic microorganisms |
550 |
213 |
Bacteriological examination of urethral discharge for aerobic and facultative anaerobic conditionally pathogenic microorganisms |
550 |
214 |
Bacteriological examination of the discharged prostate secretion for aerobic and facultative anaerobic conditionally pathogenic microorganisms |
550 |
215 |
Bacteriological examination of the discharge of female genital organs for aerobic and facultative anaerobic microorganisms |
550 |
216 |
Mycological examination of the discharge of female genital organs for fungi of the genus Candida (CandidAspp.) |
250 |
217 |
Bacteriological examination of semen for aerobic and facultative anaerobic microorganisms |
550 |
218 |
Bacteriological examination of uterine cavity aspirate for aerobic and facultative anaerobic microorganisms |
550 |
219 |
Study of intestinal microbiocenosis (dysbacteriosis) |
1 |
220 |
Cultural study on the dysentery group, salmonella |
350 |
221 |
Bacteriological examination of feces for Staphylococcus aureus (Staphylococcus aureus) |
300 |
222 |
Bacteriological examination of feces for conditionally pathogenic microflora |
500 |
223 |
Bacteriological examination of duodenal aspirate |
700 |
224 |
Mycological examination of feces for fungi of the genus Candida (Candida spp.) |
350 |
225 |
Immunochromatographic rapid test for the detection of Clostridium difficile toxins A and B in faeces |
1 |
226 |
Bacteriological examination of blood for sterility |
700 |
227 |
Bacteriological examination of blood for typhoid-paratyphoid group of microorganisms |
170 |
228 |
Bacteriological examination of the detachable conjunctiva (tear fluid) on aerobic and facultative anaerobic conditionally pathogenic microorganisms |
550 |
229 |
Microbiological examination of urine for aerobic and facultative anaerobic conditionally pathogenic microorganisms |
550 |
230 |
Test for yeast-like fungi (Candida spp.) cultural method |
350 |
231 |
Determination of the sensitivity of microorganisms to antibiotics and other drugs |
450 |
232 |
Bacteriological examination of wound discharge for aerobic and facultative anaerobic microorganisms |
550 |
233 |
Bacteriological study of purulent discharge for aerobic and facultative anaerobic microorganisms |
550 |
234 |
Microbiological examination of a smear from the skin |
550 |
235 |
Mycological examination of skin scrapings for fungi of the genus Candida (Candida spp.) |
250 |
236 |
Bacteriological study of bile for aerobic and facultative anaerobic microorganisms |
350 |
237 |
Microbiological examination of breast milk for microflora |
550 |
238 |
Determination of the sensitivity of microorganisms to antibiotics and other drugs |
150 |
239 |
Microbiological examination of cerebrospinal fluid for aerobic and facultative anaerobic microorganisms |
550 |
240 |
STUDY OF SEROLOGICAL MARKERS OF INFECTIONS |
|
241 |
HBsAg, qualitative test (HBs-antigen, hepatitis B surface antigen) |
300 |
242 |
Total antibodies to hepatitis C virus (anti-HCV total) |
300 |
243 |
Late antibodies with core-AG of hepatitis B virus (Anti-HBc IgG) |
430 |
244 |
Early antibodies with core-AG of hepatitis B virus (Anti-HBc IgМ) |
550 |
245 |
Antibodies to Hbs antigen of hepatitis B virus (Anti-Hbs) |
490 |
246 |
Antibodies to HBe antigen of hepatitis B virus (Anti-HBE) |
430 |
247 |
Early antibodies (IgM) to the hepatitis C virus (Anti-HCV-IgM) |
430 |
248 |
Hepatitis A, early IgM antibodies (Anti-HAV-IgM) |
730 |
249 |
Late hepatitis A virus IgG antibodies (Anti-HAV-IgG) |
630 |
250 |
late antibodies (IgG) hepatitis E virus (Anti-HEV-IgG) |
650 |
251 |
Total antibodies to hepatitis D virus (Аnti-HDV total) |
430 |
252 |
Early antibodies to hepatitis D virus (Аnti-HDV IgM) |
720 |
253 |
RPR test for Treponema pallidum (anticardiolipin test) |
310 |
254 |
Total antibodies to Treponema pallidum (IgG, IgM) |
365 |
255 |
Late antibodies to Treponema pallidum (IgG) |
365 |
256 |
Early antibodies to Treponema pallidum (IgM) |
650 |
257 |
Determination of IgM antibodies to coronavirus infection SARS-Co-V-2 using ELISA (blood analysis) |
800 |
258 |
Determination of IgG antibodies to coronavirus infection SARS-Co-V-2 using ELISA (blood analysis) |
800 |
259 |
Determination of IgM and IgG antibodies to coronavirus infection SARS-Co-V-2 using ELISA (blood analysis) |
1 |
260 |
Antibodies to HIV 1 and 2 and HIV antigen 1 |
275 |
261 |
secretory antibodies (IgA) к Chlamidia pneumoniae |
520 |
262 |
Antibodies (IgМ/IgG) к Mycoplasma pneumoniae |
880 |
263 |
late antibodies (IgG) к Mycoplasma hominis |
540 |
264 |
secretory antibodies (IgA) к Toxoplasma gondii |
540 |
265 |
Antibodies of the IgM and IgG classes; determination of IgG avidity to Toxoplasma gondii |
1 |
266 |
late antibodies (IgG) to herpes simplex virus 1 and 2 types |
460 |
267 |
Early antibodies (IgM) to herpes simplex virus 1 and 2 types |
475 |
268 |
Antibodies of the IgM and IgG classes; determination of IgG avidity to herpes simplex virus 1 and 2 types |
1 |
269 |
late antibodies (IgG) to human herpesvirus type 8 |
580 |
270 |
late antibodies (IgG) to human herpesvirus type 6 |
500 |
271 |
late antibodies (IgG) k cytomegalovirus (Cytomegalovirus) |
380 |
272 |
Early antibodies (IgM) k cytomegalovirus (Cytomegalovirus) |
505 |
273 |
Antibodies of the IgM and IgG classes; determination of IgG avidity to cytomegalovirus (Cytomegalovirus) |
1 |
274 |
late antibodies (IgG) to the rubella virus (Rubella virus) |
410 |
275 |
Early antibodies (IgM) to the rubella virus (Rubella virus) |
540 |
276 |
Antibodies of the IgM and IgG classes; determination of IgG avidity to rubella virus (Rubella virus) |
1 |
277 |
Complex of studies on TORCH-infection IgG/IgM, avidity |
3 |
278 |
late antibodies (IgG) to Helicobacter (Helicobacter pylori) |
440 |
279 |
secretory antibodies (IgA) to Helicobacter (Helicobacter pylori) |
580 |
280 |
Early antibodies (IgM) to Helicobacter (Helicobacter pylori) |
580 |
281 |
Helicobacter pylori antigen (Helicobacter pylori) in feces |
720 |
282 |
IgM antibodies to tick-borne encephalitis virus |
510 |
283 |
IgG antibodies to tick-borne encephalitis virus |
510 |
284 |
Early antibodies (IgM) to pathogens of ixodid tick-borne borreliosis of the Borrelia burgdorferi group |
470 |
285 |
Late antibodies (IgG to ixodid tick-borne borreliosis pathogens of the Borrelia burgdorferi group |
420 |
286 |
Infectious mononucleosis VCA- IgM |
490 |
287 |
Infectious mononucleosis EA-IgG (to the early antigen) |
480 |
288 |
Infectious mononucleosis NA-IgG |
490 |
289 |
Infectious mononucleosis VCA- IgG |
620 |
290 |
late antibodies (IgG) to toxocar antigens |
540 |
291 |
late antibodies (IgG) to the varicella-zoster virus and herpes zoster (Varicella-Zoster virus |
640 |
292 |
Early antibodies (IgM) to the varicella-zoster virus and herpes zoster (Varicella-Zoster virus) |
715 |
293 |
Early antibodies (IgM) к Bortedella pertussis (whooping cough) |
730 |
294 |
secretory antibodies (IgA) к Bortedella pertussis (whooping cough) |
730 |
295 |
late antibodies (IgG) к Bortedella pertussis (whooping cough) |
730 |
296 |
Early antibodies (IgM) to the measles virus |
640 |
297 |
late antibodies (IgG) to the measles virus |
740 |
298 |
RPHA with typhus diagnosticum |
400 |
299 |
secretory antibodies (IgA) кYersinia Enterocolitica |
485 |
300 |
late antibodies (IgG) кYersinia Enterocolitica |
485 |
301 |
Antibodies to Salmonella typhi (typhoid fever) (RPG) |
495 |
302 |
Comprehensive study of antibodies to helminths:opisthorchiasis, Echinococcosis, toxocarosis, trichinellosis |
1 |
303 |
Total antibodies to Lamblia intestinalis (IgA, IgG, IgM) |
660 |
304 |
late antibodies (IgG) к Opistorchis Felineus (opisthorchiasis) |
740 |
305 |
Antibodies of the IgM classes, IgG and CEC to opisthorchis antigens |
690 |
306 |
Antibodies of the IgG class to trichinella antigens (anti-Trichinella IgG) |
500 |
307 |
Anti-Echinococcus-IgG (IgG class antibodies to echinococcus antigens) |
740 |
308 |
STUDY OF INFECTIONS BY PCR METHOD |
|
309 |
Hepatitis B DNA (Hepatitis B virus) quantitative research |
2 |
310 |
hepatitis C virus RNA (Hepatitis C virus) quantitative research |
2 |
311 |
Hepatitis B DNA (Hepatitis B virus) qualitative research |
385 |
312 |
hepatitis C virus RNA (Hepatitis C virus) qualitative research |
675 |
313 |
Determination of the genotype of the hepatitis C virus (Hepatitis C virus) |
825 |
314 |
hepatitis D virus RNA (Hepatitis D virus) qualitative research |
585 |
315 |
hepatitis G virus RNA |
585 |
316 |
Chlamydia trachomatis DNA (Chlamidia trachomatis) |
320 |
317 |
DNA Ureaplasma urealiticum (Ureaplasma urealyticum) |
320 |
318 |
DNA Ureaplasma parvum (Ureaplasma minor) |
320 |
319 |
DNA Ur.urealiticum and Ur.parvum |
550 |
320 |
Mycoplasma hominis DNA (Mycoplasma of man) |
320 |
321 |
DNA Mycoplasma genitalium (Mycoplasma genitalia) |
320 |
322 |
Trichomonas DNA (Trichonomas vaginalis) |
320 |
323 |
Gardnerella DNA (Gardnerella vaginalis) |
320 |
324 |
DNA Gonococcus (N. Gonorrhoeae) |
320 |
325 |
DNA Candida (Candida albicans) |
320 |
326 |
DNA Treponema (Treponema pale) |
310 |
327 |
DNA Mycoplasma (Micoplasma pneumoniae) |
385 |
328 |
Testing for a new coronavirus infection (COVID-19)- PCR method (excluding material intake) |
1 |
329 |
Testing for a new coronavirus infection (COVID-19)- PCR method (taking into account the material intake) |
1 |
330 |
Testing for a new coronavirus infection (COVID-19)- PCR method (with the departure of an employee to collect material) |
1 |
331 |
Testing for a new coronavirus infection (COVID-19)- PCR method (urgent test) |
3 |
332 |
chickenpox virus DNA (Varicella Zoster Virus) |
300 |
333 |
Herpes simplex virus DNA 1,2 type (HSV-1,2) |
450 |
334 |
Herpes simplex virus DNA 6 (Herpes simplex virus 6) |
320 |
335 |
Herpes simplex virus DNA 8 (Herpes simplex virus 8) |
320 |
336 |
Epstein-Barr virus DNA (EBV) |
320 |
337 |
Epstein-Barr virus DNA (EBV) quantitation |
385 |
338 |
DNA Human papillomavirus HPV-16.18 quality |
375 |
339 |
DNA Human papillomavirus HPV-6.11 |
375 |
340 |
DNA Human papillomavirus HPV-31,33 type |
375 |
341 |
DNA Human papillomavirus HPV-high carcinogenic risk (16,18,31,33,35,39,44,45,51,52,56,58,59 types) |
990 |
342 |
HPV DNA 21 type (6, 11, 16, 18, 26, 31, 33, 35, 39, 44, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82) |
2 |
343 |
DNA Toxoplasmosis (Toxoplasma gondii) |
320 |
344 |
RNA Rubella virus (for.Rubella ) |
595 |
345 |
DNA Cytomegalovirus (SMV) qualitative |
400 |
346 |
DNA Cytomegalovirus (SMV) quantitative |
400 |
347 |
TBE virus RNA |
550 |
348 |
ДНК Borrelia burgdorferi |
550 |
349 |
TBE virus RNA and Borrelia burgdorferi DNA |
850 |
350 |
TBE virus antigen in blood |
550 |
351 |
ДНК Rickettsia species |
550 |
352 |
Comprehensive study of the tick (РНК Tick-borne encephalitis Virus, ДНК Borrelia burgdorferi s.l., Anaplasma, Ehrlichia) with differentiation |
1 |
353 |
ДНК Anaplasma phagocytophilum, Ehrlichia muris, Ehrlichia chaffeensis |
750 |
354 |
STUDY OF IMMUNE STATUS PARAMETERS |
|
355 |
Immunoglobulin A, IgA |
240 |
356 |
Immunoglobulin G, IgG |
240 |
357 |
Immunoglobulin M, IgM |
240 |
358 |
Immunoglobulin E, IgE |
430 |
359 |
STUDY OF ANTIBODIES TO ALLERGENS, SENSITIZATION DETECTION |
|
360 |
STUDY OF ANTIBODIES TO TISSUE ANTIGENS AND SECRETS (autoimmune diseases) |
|
361 |
Rheumatoid factor (RF), (blood) |
350 |
362 |
Lupus Antcoagulant (THE) |
770 |
363 |
citrullinated vimentin (Sa-antigen), IgG antibodies) |
1 |
364 |
Antibodies to cyclic citrulline-containing peptide (anti-ССP) |
1 |
365 |
Antisperm antibodies |
870 |
366 |
Antibodies to smooth muscle (ASMA) |
1 |
367 |
Antibodies to thyroperoxidase (AT-TPO) |
400 |
368 |
Antibodies to thyroglobulin (AT-TG) |
420 |
369 |
Antibodies to the microsomal fraction of thyrocytes |
470 |
370 |
Thyroglobulin (TG) |
550 |
371 |
thyroxine-binding globulin (TSG) |
480 |
372 |
Antibodies to the TSH receptor |
1 |
373 |
Globulin, sex hormone binding (GSPG) |
400 |
374 |
Antibodies to cardiac muscle |
1 |
375 |
Antibodies to liver and kidney microsomes (LKM-1) |
1 |
376 |
Antibodies to cardiolipin total (qualitative) |
950 |
377 |
Antibodies to cardiolipin (IgG) |
650 |
378 |
Antibodies to cardiolipin (IgM) |
900 |
379 |
Antibodies to the cytoplasm of neutrophils (ANCA) |
1 |
380 |
Antimitochondrial antibodies (BUT) |
1 |
381 |
Class G antibodies to double stranded (native) DNA / anti-dsDNA |
580 |
382 |
Antibodies to platelets |
1 |
383 |
Antinuclear antibodies / Antinuclear antibodies (ANAs, EIA) |
510 |
384 |
Spectrum of antinuclear antibodies (Sm, Sm/RNP, SSA SSB Jo-1, CENP-B, ScL-70) |
3 |
385 |
ANA profile (16 indicators: nRNP/Sm, Sm, RNP 70 -A -C, SS-A, Ro-52, SS-B, Scl-70, PM-Scl, Jo-1, CENP B, PCNA, dsDNA, Nucleosomes, Histone, Rib. P-Protein, AMA-M2, BlotAnalysis) |
2 |
386 |
Myositis profile (7 indicators: Mi-2, To, Pm-Scl, Jo-1, PL-7, PL-12,Ro-52, BlotAnalysis) |
3 |
387 |
autoimmune liver disease (9 indicators: AMA-M2, M2-3E (BPO), Sp100, PML, gp210, LKM-1, LC-1, SLA/LP,Ro-52, BlotAnalysis) |
3 |
388 |
antiperinuclear factor (APF) |
1 |
389 |
Antibodies to insulin (blood) |
530 |
390 |
Antibodies to pancreatic beta cells (blood) |
1 |
391 |
Antibodies to glutamate decarboxylase (blood; Anti-GAD IgG) |
1 |
392 |
β-2-Glycoprotein I, IgG antibodies |
1 |
393 |
β-2-Glycoprotein I, IgM antibodies |
1 |
394 |
Annexin V, IgG antibodies, (apoptosis marker) |
1 |
395 |
Annexin V, IgM antibodies |
1 |
396 |
STUDY OF ANTIGENS OF BLOOD CELLS AND ALLOIMMUNE ANTIERYTHROCYTE ANTIBODIES |
|
397 |
Blood type ((A, AT, 0) |
200 |
398 |
Rh factor (Rh) |
200 |
399 |
Rh (C, E, c, e), Kell - phenotyping (Rh C, E, c, e, Kell phenotyping) |
630 |
400 |
Alloimmune antibodies (including antibodies to Rh antigen) |
490 |
401 |
MORPHOLOGICAL AND IMMUNOHISTOCHEMICAL STUDIES |
|
402 |
DRUG METABOLISM STUDIES |
|
403 |
MOLECULAR GENETIC STUDIES (oncogenetics, hereditary diseases) |
|
404 |
Typing of the genes of the HLA class II system (DRB1, DQA1, DQB1) |
4 |
405 |
Bechterew's disease (HLA-B27) |
750 |
406 |
hereditary hyperbilirubinemia (Gilbert's syndrome) UGT1A1 |
3 |
407 |
Viewing a Histological Preparation |
1 |
408 |
Remote description and interpretation of histological slides using telemedicine technologies |
2 |
409 |
Pathological and anatomical study of the biopsy (operational) material of the first category of complexity |
680 |
410 |
Pathological and anatomical study of the biopsy (operational) material of the second category of complexity |
1 |
411 |
Pathological and anatomical study of the biopsy (operational) material of the third category of complexity |
1 |
412 |
Pathological and anatomical study of the biopsy (operational) material of the fourth category of complexity |
2 |
413 |
Pathological and anatomical study of the biopsy (operational) material of the fifth category of complexity |
3 |
414 |
Molecular genetic study of mutations in the BRCA1 and BRCA2 genes in the blood |
5 |
415 |
Molecular genetic study of mutations in the CHEK2 gene in the blood by PCR |
3 |
416 |
Molecular genetic study of mutations in the EGFR gene in the blood by PCR |
12 |
417 |
Molecular genetic study of mutations in the KRAS gene in a biopsy (operational) material |
8 |
418 |
Molecular genetic study of mutations in the NRAS gene in a biopsy (operational) material |
5 |
419 |
Molecular genetic study of mutations in the BRAF gene in a biopsy (operational) material |
5 |
420 |
Molecular genetic study of mutations in the BRCA1 gene in a biopsy (operational) material |
8 |
421 |
Molecular genetic study of mutations in the BRCA2 gene in a biopsy (operational) material |
2 |
422 |
Molecular genetic study of mutations in the c-KIT gene in a biopsy (operational) material |
12 |
423 |
Molecular genetic study of mutations in the EGFR gene in a biopsy (operational) material |
18 |
424 |
Molecular genetic study of ALK gene translocations |
12 |
425 |
Molecular genetic study of ROS1 gene translocations |
12 |
426 |
Determination of microsatellite instability in a biopsy (operational) material by PCR |
10 |
427 |
Molecular genetic study of mutations in the BRCA gene in a biopsy (operational) material by NGS method |
35 |
428 |
Determination of PDL1 protein expression (SP263) immunohistochemical method |
12 |
429 |
Determination of PDL1 protein expression (22C3) immunohistochemical method |
15 |
430 |
Determination of PDL1 protein expression (SP142) immunohistochemical method |
12 |
431 |
Determination of PDL1 protein expression (28-8) immunohistochemical method |
12 |
432 |
Pathological and anatomical study of the protein to HER2/neu receptors using immunohistochemical methods |
6 |
433 |
Molecular genetic study of mutations in the PIK3CA gene |
12 |
434 |
Molecular genetic study of mutations in the HER2/neu gene (overexpression) |
10 |
435 |
Molecular genetic study in colorectal cancer (BRAF, KRAS, NRAS) (qualitative) |
15 |
436 |
Microdeletions of AZFa loci, AZFb, AZFc Y chromosomes |
1 |